| 2.84 0.12 (4.41%) | 02-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.43  |
1-year : | 4.01 |
| Resists | First : | 2.94 |
Second : | 3.43 |
| Pivot price | 2.47 |
|||
| Supports | First : | 2.35 |
Second : | 1.99 |
| MAs | MA(5) : | 2.59 |
MA(20) : | 2.4 |
| MA(100) : | 2.36 |
MA(250) : | 3.62  |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 85.5 |
D(3) : | 73.6 |
| RSI | RSI(14): 68.4 |
|||
| 52-week | High : | 8.85 | Low : | 1.62 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BCDA ] has closed above the upper band by 8.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 11.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.94 - 2.95 | 2.95 - 2.96 |
| Low: | 2.66 - 2.67 | 2.67 - 2.69 |
| Close: | 2.82 - 2.84 | 2.84 - 2.85 |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Thu, 13 Feb 2025
Clinical Trial Milestone: BioCardia's Revolutionary Heart Failure Treatment Advances to Next Phase - StockTitan
Mon, 27 Jan 2025
BioCardia to Present CardiAMP Phase 3 Heart Failure Trial Results at ACC 2025 - StockTitan
Thu, 26 Dec 2024
Biocardia CEO Peter Altman acquires shares worth $2,060 - Investing.com
Thu, 19 Dec 2024
BioCardia stock plunges to 52-week low of $1.81 amid market challenges - Investing.com
Tue, 17 Dec 2024
BioCardia Launches Revolutionary Morph DNA Steerable Introducer, Advances Breakthrough Heart Failure Therapy - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 1.6e+006 (%) |
| Held by Institutions | 14 (%) |
| Shares Short | 132 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.53e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -54 % |
| Return on Assets (ttm) | 966.6 % |
| Return on Equity (ttm) | -116 % |
| Qtrly Rev. Growth | 428000 % |
| Gross Profit (p.s.) | -73.23 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.65354e+006 |
| Qtrly Earnings Growth | -4.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.54 |
| Dividend | 0 |
| Forward Dividend | 86280 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|